Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

Cancer Policy

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.

October 24, 2025

Vol.51 No.39

By Sara Willa Ernst

Clinical Regulatory News Trials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).

October 17, 2025

Vol.51 No.38

By Edison T. Liu

News Analysis Regulatory News

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter and Jacquelyn Cobb

Guest Editorial

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

When the idea of looking at cancer center funding and the cancer burden of cancer center catchment areas came to us in the summer of 2024, we lived in a different context.

October 17, 2025

Vol.51 No.38

By Todd Burus, Caree McAfee and Pamela C. Hull

Cancer Policy

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

NIH has published a policy that prohibits U.S. researchers and NIH grant recipients working with human biospecimens to share this data with “countries of concern.” That list includes China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela.

October 10, 2025

Vol.51 No.37

By Sara Willa Ernst

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

Early endpoints are a balance of risk and benefit

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Renew today!

Subscriber content

Never miss an issue!

Login

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

Early endpoints are a balance of risk and benefit

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Never miss an issue!

Login

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough